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Abstract
Purpose As no curative treatment for advanced pancre-
atic and biliary cancer with malignant ascites exists, new
modalities possibly improving the response to available
chemotherapies must be explored. This phase I study
assesses the feasibility, tolerability and pharmacokinetics of
a regional treatment of gemcitabine administered in escalat-
ing doses by the stop-Xow approach to patients with
advanced abdominal malignancies (adenocarcinoma of the
pancreas, n = 8, and cholangiocarcinoma of the liver,
n = 1).
Experimental design Gemcitabine at 500, 750 and
1,125 mg/m2 was administered to three patients at each
dose level by loco-regional chemotherapy, using hypoxic
abdominal stop-Xow perfusion. This was achieved by an
aorto-caval occlusion by balloon catheters connected to an
extracorporeal circuit. Gemcitabine and its main metabolite
2,2-diXuorodeoxyuridine (dFdU) concentrations were
measured by high performance liquid chromatography with
UV detection in the extracorporeal circuit during the
20 min of stop-Xow perfusion, and in peripheral plasma for
420 min. Blood gases were monitored during the stop-Xow
perfusion and hypoxia was considered stringent if two of
the following endpoints were met: pH · 7.2, pO2 nadir
ratio ·0.70 or pCO2 peak ratio ¸1.35. The tolerability of
this procedure was also assessed.
Results Stringent hypoxia was achieved in four patients.
Very high levels of gemcitabine were rapidly reached in the
extracorporeal circuit during the 20 min of stop-Xow perfu-
sion, with Cmax levels in the abdominal circuit of 246
(§37%), 2,039 (§77%) and 4,780 (§7.3%) g/ml for the
three dose levels 500, 750 and 1,125 mg/m2, respectively.
These Cmax were between 13 (§51%) and 290 (§12%)
times higher than those measured in the peripheral plasma.
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332 Cancer Chemother Pharmacol (2009) 63:331–341Similarly, the abdominal exposure to gemcitabine, calcu-
lated as AUCt0–20, was between 5.5 (§43%) and 200
(§66%)-fold higher than the systemic exposure. Loco-
regional exposure to gemcitabine was statistically higher in
presence of stringent hypoxia (P < 0.01 for Cmax and
AUCt0–20, both normalised to the gemcitabine dose). Toxic-
ities were acceptable considering the complexity of the pro-
cedure and were mostly hepatic; it was not possible to
diVerentiate the respective contributions of systemic and
regional exposures. A signiWcant correlation (P < 0.05) was
found between systemic Cmax of gemcitabine and the nadir
of both leucocytes and neutrophils.
Conclusions Regional exposure to gemcitabine—the cur-
rent standard drug for advanced adenocarcinoma of the
pancreas—can be markedly enhanced using an optimised
hypoxic stop-Xow perfusion technique, with acceptable
toxicities up to a dose of 1,125 mg/m2. However, the activ-
ity of gemcitabine under hypoxic conditions is not as Wrmly
established as that of other drugs such as mitomycin C,
melphalan or tirapazamine. Further studies of this investi-
gational modality, but with bioreductive drugs, are there-
fore warranted Wrst to evaluate the tolerance in a phase I
study and later on to assess whether it does improve the
response to chemotherapy.
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Introduction
Cancer of the exocrine pancreas represents a major health
burden in developed countries. In the United States, it was
reported in 2000 as the fourth leading cause of cancer-
related death for both men and women, while in Europe it
ranked sixth [1]. Because of diYculties in diagnosis, the
aggressiveness of tumour growth and the lack of eVective
systemic therapies, the one and Wve year survival rates
remain below 25 and 5%, respectively [1, 2].
Considering the very poor prognosis of advanced pan-
creatic cancer with malignant ascites, and the absence of
eYcient new drugs, innovative modalities that may possi-
bly improve, even modestly, the clinical response to avail-
able chemotherapies deserve exploration. A phase I study
was therefore initiated, aiming at assessing the feasibility,
tolerability and pharmacokinetics of a regional chemothera-
peutic treatment of gemcitabine administered by the stop-
Xow technique. The stop-Xow concept was introduced in
1993 by Aigner as a semi-invasive loco-regional drug
delivery approach [3]: the pharmacokinetic exposure to
intra-arterial chemotherapy can be markedly enhanced
when the arterial blood Xow is reduced immediately after
drug injection. To that purpose, Aigner et al. suggested to
inXate a balloon catheter in the main aVerent artery to slow
down drug wash-out (arterial inXow occlusion). Pancreatic,
gastric and pelvic tumours as well as peritoneal carcinoma-
tosis are the main potential indications for this approach.
However, the increase in drug exposure remains limited by
the unavoidable drug wash out from the target organ into
the venous stream. Thus, in order to further increase drug
exposure during stop-Xow, it may be possible, to add a
venous outXow occlusion to establish a recirculation perfu-
sion circuit (Fig. 1). This stop-Xow perfusion technique is
well suited for large body segments such as the thoracic and
abdominal cavities in the pelvis and the limb [3–5].
There is currently controversy regarding the eYcacy of
such treatments: the Wrst stop-Xow trials (1993–1996) were
promising with overall tumour responses up to 57% [4, 6],
but later trials (1998–present) were unable to conWrm these
results [7–10]. However, the distribution and concentra-
tions of the antineoplastic drugs in the regional and sys-
temic compartments of the circuit have not been thoroughly
studied. To the best of our knowledge, only one clinical
pharmacokinetic trial has been published in this setting
[10]. Given this limited information, there is a need to
deWne more precisely the local and systemic disposition of
anticancer drugs administered through this manner before
phase II or III trials are undertaken.
Gemcitabine chemotherapy is presently the standard of
care for advanced pancreatic adenocarcinoma and has a
favourable safety proWle when administered systemically.
This is why this drug was selected for this “proof-of-con-
Fig. 1 Abdominal stop-Xow perfusion (from Pilati et al. [5]). IVC,
inferior vena cava; A, aorta; D, diaphragm123
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oxic conditions is not known.
This phase I study assesses the feasibility and tolerability
of a regional treatment of gemcitabine administered by
hypoxic abdominal stop-Xow perfusion to patients with
advanced pancreatic cancer or refractory malignant ascites.
It also describes the regional and systemic pharmacokinetic
proWles of gemcitabine and its main metabolite 2,2-diXu-
orodeoxyuridine (dFdU).
Methods
Patients
This phase I study was approved by the local Ethics Com-
mittee of our Institution. At inclusion, all patients suVered
from a histologically proven stage II, III or IV carcinoma of
the pancreas that had been treated according to current state
of the art (resection or bypass surgery, interventional
endoscopy or radiology, palliative radiotherapy, systemic
chemotherapy). Stage II patients were included in case of
residual disease or failure of radical resection; stage III
patients were included in all cases, and stage IV patients
exclusively if intra-abdominal metastases were the only site
of dissemination. Patients suVering from malignant ascites
due to intra-abdominal carcinomas, resistant to conven-
tional treatments could also be included. Patients had to be
older than 18 years of age, have a performance score of less
than or equal to 2 on the Eastern Cooperative Oncology
Group (ECOG) scale, and have intact liver and renal func-
tion tests. All gave informed written consent and knew that
the protocol did not aim at cure. None had signiWcant car-
diac failure (New-York Medical Heart Association, classes
III and IV), severe disease of the central nervous system
(tumours, psychiatric disorders, stroke), peripheral arterial
disease (grade II or more according to Fontaine), an organ
allograft, haemorrhagic diathesis, active infectious disease,
an active peptic ulcer, a history of deep vein thrombosis or
a previous radiotherapy treatment involving more than 20%
of haematopoietic bone marrow.
Study design
The primary study endpoint was the assessment of the
pharmacokinetic proWle and tolerability of gemcitabine
administered by stop-Xow perfusion. The evaluation of
gemcitabine anti-tumoral eVect was a secondary endpoint.
All patients were scheduled to receive subsequent sys-
temic gemcitabine treatments (1,000 mg/m2 every week
for 3 weeks, followed by 1 week oV) after closure of the
study.
Three dose levels of gemcitabine were tested in ascending
order in three sets of patients. The initial dose level was cho-
sen at 500 mg/m2 (i.e. 50% of a usual weekly dose by intra-
venous infusion), and subsequent escalations were by 50%
steps (i.e. 750 and 1,125 mg/m2). In case of a dose-limiting
toxicity (DLT), an additional three patients had to be treated
at the same dose level. Treatment at an escalated dose was
only given if less than three of six patients had experienced a
toxic adverse event. DLT was deWned as a lasting grade III or
any grade IV toxicity according to the common terminology
criteria for adverse events (CTCAE) [11].
Stop-Xow procedure
The stop-Xow procedure was performed under general
anesthaesia by introducing an arterial balloon catheter into
the aorta via the common femoral artery up to the dia-
phragm and a venous balloon catheter via the sapheno-fem-
oral junction up to the right atrium under radioscopic and
radio-angiographic control (Fig. 1). Systemic anticoagula-
tion was achieved with heparin (150 U/kg). An extra-
corporeal circuit (without a blood oxygenator) was then
connected, draining the blood from the vena cava and re-
infusing it into the aorta. This circuit was primed with
200 ml of Hartmann solution and 5,000 U heparin and
started at a Xow rate of 100 ml/min. After checking of the
balloons’ position, the circulation in the lower limbs was
interrupted by pneumatic cuVs at the root of the thighs and
aorto-caval Xow block was achieved by inXating the bal-
loon catheters. The Xow of the circuit was set between 100
and 300 ml/min according to blood outXow capacity. A
gemcitabine bolus was then injected into the circuit and
allowed to circulate in the abdomen until the end of a
20 min stop-Xow period.
At the end, blood circulation was re-established by
deXating Wrst the caval catheter balloon, then the aortic one
and Wnally by removing the limb cuVs. The balloon cathe-
ters were removed and the vessels sutured.
The level of hypoxia reached during the stop-Xow proce-
dure was considered stringent if at least two of the follow-
ing three criteria were met: pH · 7.2, pO2 nadir ratio
·0.70 mmHg and pCO2 peak ratio ¸1.35 mmHg.
Optimization of caval balloon positioning
In spite of an apparently complete venous block at the vena
cava’s level, as assessed by angiography, transoesophageal
ultrasonography revealed residual blood Xow in some
patients, which could have caused signiWcant drug leakage
into the systemic circulation. In this situation, ultrasonogra-
phy enabled the surgeon to optimalise the vena cava’ bal-
loon position at the level of right atrium.123
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The patients were monitored closely during the month fol-
lowing the stop-Xow procedure and had weekly medical
visits. Tolerance of the stop-Xow perfusion with gemcita-
bine was evaluated for 3 weeks: haematologic parameters
were checked three times a week, while renal and hepatic
functions were controlled three times during the Wrst week
and then weekly. The common terminology criteria for
adverse events (CTCAE) was used to grade organ damage
[11].
In patients with pancreas carcinoma, the anti-tumoral
eVect was assessed by CT-scan 2 months after treatment
and then every 3 months. The markers carbohydrate anti-
gen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA)
were checked every month. In case of malignant ascites, the
umbilical perimeter was measured and CT-scan evaluation,
in case of a tumoral mass, was done as above. Depending
on the tumour histology, other markers were also followed.
Pharmacokinetics
Samples
Blood samples were collected into heparinised tubes
(Monovettes® 5.5 ml, Sarstedt, Nümbrecht, Germany)
added with 50 l of the cytidine deaminase inhibitor tetra-
hydrouridine (THU; 1 mg/ml solution) from Calbiochem
(supplied by Juro, Luzern, Switzerland). Arterial blood
samples were collected from the extracorporeal circuit
before and then at 2, 4, 6, 8, 10, 15 and 20 min after gemcit-
abine injection in the perfusion circuit. Peripheral venous
blood samples were collected before and at 2, 4, 6, 8, 10,
15, 20, 25, 30, 35, 40, 50, 60, 90 min, and then 2, 3, 4, 6 h
after gemcitabine injection. Plasma was separated by cen-
trifugation at 1,500g for 10 min. All samples were stored at
¡20°C until analysis.
Analytical method
The plasma concentrations of gemcitabine and its inactive
metabolite dFdU were determined by a normal-phase HPLC
method with UV detection. Gemcitabine HCl (LY2643689)
and dFdU (LY198791) were generously supplied by Eli
Lilly (Indianapolis, USA). The related compound lamivu-
dine (3TC®) was purchased from GlaxoSmithKline (Mün-
chenbuchsee, Switzerland) to be used as internal standard.
BrieXy, a 1 ml-sample aliquot was spiked with 100 l of
internal standard aqueous solution (12.5 g/ml) prior to the
protein precipitation step. Then, 500 l acetone (E. Merck,
Darmstadt, Germany) and 50 l zinc sulphate (E. Merck,
Darmstadt, Germany) 70% aqueous solution were added.
The samples were mixed and centrifuged at 22,000g for
10 min at +4°C. The supernatant was evaporated to dryness
at 60°C for 75 min under nitrogen stream and the solid
residue was resuspended in 150 l methanol (E. Merck,
Darmstadt, Germany) and sonicated for 15 min. The non-
solubilised solid residue was eliminated by centrifugation at
22,000g for 20 min at 4°C. The particle-free samples were
introduced into HPLC 0.5 ml amber glass vials (i.e. pro-
tected from light) (Laubscher Labs, Miecourt, Switzerland).
A volume of 10 l was subjected to HPLC analysis onto a
YMC-pack polyamine II column, 250 mm £ 4.6 mm i.d.,
S-5 m, 12 nm (YMC, Schermbeck, Germany) equipped
with a YMC-pack polyamine II guard column,
10 mm £ 4 mm i.d. Wlled with the same packing material
(YMC, Schermbeck, Germany). The mobile phase was
delivered using a gradient elution of acetonitrile (E. Merck,
Darmstadt, Germany) and an aqueous solution containing
30 mM of ammonium formate (Fluka, Buchs, Switzerland)
adjusted to pH 5.5 with formic acid 1%: 95/5 at
0 min ! 85/15 at 22 min, ! 0/100 at 27 min, ! 0/100 at
42 min, ! 95/5 at 57 min, ! 95/5 at 65 min delivered at
1 ml/min (0.8 ml/min between 27 and 42 min, washing
time). The analytes were detected using a spectrophotomet-
ric UV-DAD detector set at 272 nm. The retention times for
dFdU, lamivudine and gemcitabine are 11.2, 13.4 and
18.5 min respectively. Calibration curves were obtained by
quadratic weighted 1/concentration2 (1/x2) least-squares lin-
ear regression analysis of the peak ratio of gemcitabine and
dFdU to internal standard, versus the corresponding concen-
tration ratio in each standard solution. The calibration
curves were linear over the range of 0.050–10 g/ml for
gemcitabine and 0.075–10 g/ml for dFdU. The method
was validated according to the FDA and SFSTP (Société
Française des Sciences et Techniques Pharmaceutiques)
recommendations [12, 13] as well as the guidelines of the
Washington Conference [14, 15]. The method was found to
be precise with coeYcients of variation (CV%) within 3.6–
6.8%, and accurate with 95% conWdence limits comprised
between 6.9 and 13.4% for gemcitabine and dFdU at the
three quality control samples’ concentration level. The limit
of detection was experimentally determined to 0.0125 g/
ml for gemcitabine and 0.01875 g/ml for dFdU.
Pharmacokinetic data analysis
The maximum plasma concentration (Cmax) and the time to
maximum (tmax) were determined by direct data examina-
tion for gemcitabine and dFdU in the extracorporeal system
and in the peripheral plasma. The terminal half-life (t1/2term)
was calculated in the peripheral plasma as Log(2)/z, where
z represents the terminal elimination rate constant, i.e. the
absolute value of the slope of the terminal log–linear phase.
Gemcitabine and dFdU exposures in the extracorporeal
system and in the peripheral plasma during the 20 min of123
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the concentration–time curve (AUC0–20) calculated by the
linear trapezoidal rule. The total systemic drug exposure
was expressed as the area under the concentration–time
curve (AUC0–1) extrapolated to inWnity, deduced from the
terminal elimination rate constant z. Regional versus sys-
temic drug exposure ratios were obtained by dividing the
regional Cmax and AUCt0–20 values by the corresponding
systemic values for each patient.
All the data were calculated separately for each patient.
The results are presented as geometric mean and relative
coeYcient of variation (CV, %) at each drug dose level. A
Student’s T test was used to assess diVerences amongst the
PK parameters between patients with and without stringent
hypoxia during perfusion. Statistical signiWcance was
assumed at P < 0.05.
Results
Patients’ characteristics
From September 1997 to October 2002, nine patients were
included in the study. Patients’ demographics are described
in Table 1. The male/female ratio was 6/3. The median age
was 56 years (range 45–71). All patients had a performance
status ·2. Eight patients had adenocarcinoma of the pan-
creas (patients 1–8) including three (patients 1, 5 and 6)
with liver metastases at the time of inclusion. One patient
(patient 9) suVered from an intrahepatic cholangiocarci-
noma with refractory malignant ascites.
One patient (patient 7, dose level 3) was not assessable
because of a balloon rupture after 5 min of stop-Xow perfu-
sion: the pneumatic cuVs were immediately deXated and a
second stop-Xow perfusion performed 42 min later, but no
reliable pharmacokinetic proWle could be obtained.
Hypoxia during stop-Xow
Hypoxia was considered stringent in patients 5, 6, 8 and 9.
The other perfusions did not fulWl the criteria for hypoxia to
be considered as stringent. The evolution of pH, pO2 and
pCO2 during stop-Xow are shown on Fig. 2a–c (the pH, pO2
and pCO2 data of patient 1 could not be included in Fig. 2
because of doubts regarding collection times for blood
gases testing; however, hypoxia in this patient was assessed
as non-stringent). When considering the entire series of
experiments, it is to be noticed that hypoxia was more often
stringent in the latest patients. This may be the result of
improvements in the positioning of the atrial balloons
thanks to transoesophageal ultrasonography.
Pharmacokinetic analysis
Gemcitabine pharmacokinetics
During the 20 min of stop-Xow perfusion, very high levels
of gemcitabine were rapidly reached in the abdominal–
extracorporeal circuit (Fig. 3a). The average Cmax values
achieved in the circuit were 246, 2,039 and 4,780 g/ml for
the three dose levels (500, 750 and 1,125 mg/m2), respec-
tively (Table 2). Such Cmax were 6 to 655-fold higher than
those measured in the peripheral plasma (average ratio 70,
CV 423%). The AUC0–20 values measured in the stop-Xow
circuit during perfusion exceeded by a factor of 3–333
those obtained in the peripheral circulation (average ratio
Table 1 Demographics of the 
nine patients undergoing stop-
Xow perfusion with gemcitabine
Characteristics All dose 
levels
Dose level 1 
500 mg/m2
Dose level 2 
750 mg/m2
Dose level 3 
1,125 mg/m2
Total number of patients enrolled 9a 3 3 3a
Sex
Male 6 2 3 1
Female 3 1 0 2
Age (year)
Median 56 65 52 56
Range 45–71 59–71 45–56 49–59
Performance status (ECOG)
0 0 0 0 0
1 5 1 2 2
2 4 2 1 1
Tumour type
Adenocarcinoma of the pancreas 8 3 3 2
with liver metastases 3 1 2 0
Cholangiocarcinoma of the liver 1 0 0 1a Includes one drop-out case123
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thus much higher than systemic exposure.
However, gemcitabine concentration–time proWles in the
peripheral plasma (Fig.3b) indicate that a signiWcant leak-
age occurred towards the systemic circulation throughout
stop-Xow perfusion. No burst in peripheral plasma concen-
tration was observed at the end of the perfusion, when the
balloons and cuVs were deXated. Interestingly, gemcitabine
plasma levels were lower during the Wrst 15 min of perfu-
sion in the group whose stop-Xow procedure was
performed under stringent hypoxia (patients 5, 6, 8 and 9),
even though they were receiving the upper dose levels (i.e.
level 2 for patients 5 and 6, and level 3 for patients 8 and
9): this may be explained by an improved isolation of the
extracorporeal circuit, due to the optimal sonographically
assisted atrial positioning of the venous balloon. Further
analysis conWrmed that the regional exposure to gemcita-
bine was statistically higher when hypoxia was stringent
(P = 0.004 for Cmax and P = 0.002 for AUC0–20, both nor-
malised to gemcitabine dose). The achievement of stringent
hypoxia markedly increased the regional to systemic con-
centration ratio (P = 0.02 for Cmax regional/systemic ratio
and P = 0.03 for AUC0–20 regional/systemic ratio): this sin-
gle factor explains 60% of the relative variability in both
ratio values, as the level of hypoxia is directly related to the
degree of vascular occlusion during stop-Xow. Fig. 3c pre-
sents gemcitabine concentration–time proWle in the periph-
eral plasma during and up to 240 min after stop-Xow
perfusion. Gemcitabine exhibits Wrst order elimination rate
with a mean terminal half-life (t1/2term) of 16 min. The
patients treated with the dose level of 500, 750 and
1,125 mg/m2 had systemic AUC0–1 values extrapolated to
inWnity of 6.0, 4.8 and 8.5 mg h/l, respectively. Systemic
AUC0–1 values progressed linearly with the dose and var-
ied modestly, which was not the case for regional AUC0–1
values (possibly due to confusing eVect of improvement in
balloon positioning).
dFdU pharmacokinetics
QuantiWable levels of dFdU, although lower than those of
gemcitabine, were found in the abdominal circuit and in the
peripheral plasma from the beginning of the stop-Xow pro-
cedure. This represents gemcitabine rapid metabolism into
dFdU in both compartments (Fig. 3d). The ratio of AUC0–20
of dFdU over gemcitabine was about ten times higher in
peripheral blood, suggesting either a more eYcient bio-
inactivation of gemcitabine in the systemic compartment,
or less probably a stronger elimination of dFdU in the
abdominal–extracorporeal circuit. The dFdU concentra-
tion–time proWle in peripheral plasma during stop-Xow per-
fusion and up to 420 min after the beginning of the
perfusion is shown in Fig. 3e–f. Like gemcitabine, dFdU
exhibits a Wrst order elimination rate but has a longer t1/2term
of 248 min. The remaining pharmacokinetic parameters are
listed in Table 2.
Tolerability and toxic eVects
The regional chemotherapy treatment by stop-Xow perfu-
sion was generally well tolerated. There was no technical or
haemodynamic complication during the surgical procedure
other than the balloon rupture in patient 7 described above.
Fig. 2 pH (a), pCO2 (b) and pO2 (c) evolution during stop-Xow per-
fusion. Open symbols: patients with stringent hypoxia conditions;
closed symbols: patients with non-stringent hypoxia conditions
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period. No severe abdominal complication was observed.
Patients 2 and 3 recovered spontaneously from grade 1 and
patient 6 from grade 2 diarrhoea. Patient 1 suVered from a
deep vein thrombosis 3 weeks after the stop-Xow perfusion
and patient 6 had intermittent paresis of the left limb the
day after stop-Xow that recovered spontaneously. Labora-
tory toxicities are reported in Table 3.
There were no grade 4 toxicities. Grade 3 toxicities were
mostly hepatic. No renal (creatinine) grade 3 and 4 toxicity
was noted. All grade 3 toxicities (haematologic and
hepatic) are listed in Table 3.
Concentration–toxicity relationships were also investi-
gated. A positive signiWcant correlation (r = 0.84 and 0.87,
P < 0.05) was found between the systemic Cmax of gemcita-
bine and the nadir of both leucocyte and neutrophile counts.
Responses and survival
Eight patients were evaluated for tumour response by
abdominal CT 1 month after the stop-Xow perfusion. This
evaluation was global, in the sense that the patients
received only one hypoxic perfusion that was followed by
systemic gemcitabine treatments. One patient could not be
assessed due to clinical progression of the disease and early
death 33 days after the stop-Xow perfusion. Four patients
had radiological progression of the disease: two of them
developed liver metastases and one bone metastases
(patient 6). Two patients had stable disease. Patient 9 (with
cholangiocarcinoma of the liver) had a stable abdominal-
CT picture of the hepatic tumours, but with increased asci-
tes; the disease then progressed rapidly and the patient died
2.5 months after the stop-Xow procedure.
The results available for the cancer markers CA 19-9 and
CEA, did not indicate any decrease in tumour burden dur-
ing the Wrst month after stop-Xow perfusion.
According to a Kaplan–Meier analysis, the median sur-
vival from the time of inclusion was 2.9 months (95% con-
Wdence interval: 1.4–17.7 months).
Discussion
Stop-Xow therapeutic approaches are based on the assump-
tion that neoplasms conWned to one anatomical compart-
ment can be exposed to high local concentrations of
anticancer agents by using arterial and venous balloon cath-
eters connected to an extracorporeal perfusion circuit with-
out oxygenation. The present study reports the feasability,
tolerability and pharmacokinetic proWles of gemcitabine
and its main metabolite, dFdU in nine patients. One patient
has been excluded because of a balloon rupture that
occurred during the stop-Xow procedure. In our little study
group, the characteristics of the patients were relatively
Fig. 3 Mean gemcitabine concentrations (§SEM%) measured: a in
the extracorporeal system during the 20 min of stop-Xow perfusion,
b in the peripheral plasma during 30 min and c in the peripheral plasma
during 240 min. Mean dFdU concentrations (§SEM%) measured: d in
the extracorporeal system during the 20 min of stop-Xow perfusion,
e in the peripheral plasma during 30 min and f in the peripheral plasma
during 420 min. open circle: dose level 1 (500 mg/m2) grey Wlled cir-
cle: dose level 2 (750 mg/m2); Wlled circle: dose level 3 (1,125 mg/m2)
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Cancer Chemother Pharmacol (2009) 63:331–341 339heterogeneous: eight patients had advanced adenocarci-
noma of the pancreas, with three of them having liver
metastases, and one suVering from an intrahepatic cholan-
giocarcinoma with refractory malignant ascites.
The pharmacokinetic assessments performed proved that
the exposure to gemcitabine was indeed markedly higher
in the regional circuit than in the peripheral plasma. The
exposure was, however, signiWcantly greater for patients
perfused under stringent vascular isolation conditions,
inducing deep hypoxia. In our study, the regional over sys-
temic ratios of AUC0–20 measured under non-stringent hyp-
oxic conditions (range 2.7–49) were signiWcantly lower
than those measured under stricter hypoxic conditions. The
latter values were much higher (range 23–333) than those
reported in literature for comparable abdominal or pelvic
stop-Xow perfusions [7, 10, 16–18]. Meyer et al. for exam-
ple, reported an AUC ratio of 4 [10] and Petrowski et al. of
6.5 after abdominal stop-Xow of mitomycin C [7]. In the
limited number of studies available, various drugs such as
mitomycin C and doxorubicin were administered by stop-
Xow perfusion, which makes comparisons with gemcita-
bine diYcult. However, our study highlights that hypoxic
conditions are related to the degree of vascular isolation of
the regional circuit. This deserves, therefore, very close
monitoring which is best achieved by transoesophageal
ultrasonography: to the best of our knowledge earlier stud-
ies did not use this technique.
In the present study, the Cmax levels of gemcitabine mea-
sured in the circuit were very high (up to 5,129 g/ml). By
comparison, systemic i.v. administration of similar doses
has been reported to yield peak plasma concentrations of
30–40 g/ml [19–27]. As the intracellular phosphorylation
of gemcitabine is known to be saturable [19], the beneWt of
very high gemcitabine levels remains questionable. Others
have indeed shown that gemcitabine peak levels of 4–5 g/
ml enable a maximal production rate of the pharmacologi-
cally active gemcitabine triphosphate that accumulates in
mononuclear cells [19]. Higher levels may then saturate the
rate of cellular accumulation in a majority of patients. It is,
however, not known whether gemcitabine disposition in
mononuclear cells is similar to that in tumour cells. In addi-
tion, eYcient penetration into solid tumours may require
higher gemcitabine plasma levels. The transport and cellu-
lar metabolism of gemcitabine in cancer tissues and solid
tumour masses deserve therefore further research. The
average systemic Cmax, t1/2term and AUC0–1 levels of gem-
citabine and dFdU, according to the delivered dose, com-
pare well with the pharmacokinetic data reported in the
Table 3 Toxicities according to the common terminology criteria for adverse events (CTCAE) [19]
a Patient 3 had haemoglobin levels of 73 g/l on day 3 after stop-Xow
b Patient 1 had a PAlc level of 796 U/l and a -GT level of 1,096 U/l during the fourth week following stop-Xow
c Patient 4 had an ALAT level of 317 U/l on day 4 after stop-Xow
d Patient 8 had an ASAT level of 207 U/l, an ALAT level of 258 U/l, a PAlc level of 673 U/l and a -GT level of 233 U/l during the third week
after stop-Xow
e Patient 9 had an ASAT level of 293 U/l on day 2 following stop-Xow and a -GT level of 503 U/l during the third week following stop-Xow
f Patient 9 had a LDH level of 1,238 U/l (5.5 times upper limit of normality) before treatment attributed to the disease. The LDH levels reached a
peak of 2,256 U/l, i.e. 1.8 times higher than baseline
All dose levels 500 mg/m2 750 mg/m2 1,125 mg/m2
Grade 2 Grade 3 Grade 2 Grade 3 Grade 2 Grade 3 Grade 2 Grade 3
Haematologic
Haemoglobin 5 1 1 1a 2 0 2 0
Leucopenia 2 0 0 0 1 0 1 0
Neutropenia 1 0 0 0 1 0 0 0
Thrombocytopenia 1 0 0 0 1 0 0 0
Total 5/8 1/8 1/3 1/3 2/3 0/3 2/2 0/2
Hepatic
ASAT 2 2 0 0 2 0 0 2d,e
ALAT 1 2 1 0 0 1c 0 1d
PAlc 1 2 0 1b 1 0 0 1d
-GT 1 3 0 1b 1 0 0 2d,e
Bilirubin 1 0 0 0 0 0 1 0
Total 4/8 4/8 1/3 1/3 2/3 1/3 1/2 2/2
Creatinine 0/8 0/8 0/3 0/3 0/3 0/3 0/2 0/2
LDH 1/8 1/8 1/3 0/3 0/3 0/3 0/2 1f/2123
340 Cancer Chemother Pharmacol (2009) 63:331–341literature [19–27]. This indicates that a 20 min stop-Xow
procedure does not signiWcantly modify the overall sys-
temic exposure to gemcitabine and its metabolite.
The toxicities encountered were acceptable considering
the complexity of the procedure. We did not observe
increased toxicities in the four stringent perfused patients.
However, as this sub-group is very small, the tolerability of
the procedure should be interpreted with some caution.
Overall the toxicities were mostly hepatic, but it remains
diYcult to diVerentiate between the respective contribu-
tions of systemic and regional exposures. Liver toxicities
may be favoured by the stop-Xow procedure itself, by
hypoxia and/or by the very high regional gemcitabine con-
centrations. Studies in liver transplantation may give a clue
as they indicated that the liver is highly sensitive to the
reperfusion injury mediated by reactive oxygen species
[28]. In addition, gemcitabine itself is known to cause tran-
sient elevations of liver function tests after i.v. administra-
tion in two-thirds of patients and may therefore have
contributed to the observed toxicities [29]. Interestingly, we
did not observe any gall bladder toxicity, contrary to other
authors who perform stop-Xow with mitomycin C for liver
metastases: in their study, hypoxia was essentially toxic for
the gallbladder, with ischemic cholecystitis occurring in
3/15 cases (14%) [30]. Finally, it seems that the drugs used
for general anaesthesia, including halogenated agents may
also play a signiWcant role in the observed hepatotoxicity.
In brief, several reasons, taken separately or together, may
be incriminated for the liver function tests elevations but
we feel that hypoxia was the major cause.
Even though the clinical response was not a primary
endpoint in this phase I study, the absence of any objective
therapeutic response is disappointing. This may actually
have been expected because gemcitabine, although the
standard of care in advanced adenocarcinoma of the pan-
creas, is prescribed on the basis of an improved quality of
life, with a very short actual survival increase compared to
5-FU (5.6 vs. 4.4 months) [31]. Such survival data are
therefore in line with our median survival of 2.9 months
(95% conWdence interval 1.4–17.7 months). This result
highlights the current lack of eYcacious treatment for a
malignancy with a disastrous prognostic.
In conclusion, gemcitabine may not have been the best
choice in the setting of terminal pancreatic cancer, due to
its questionable activity under hypoxic conditions. As cel-
lular bio-activation into gemcitabine-triphosphate is an
energy-dependent process, it may decrease under hypoxia.
This, in turn, may slow down DNA synthesis and protect
tumour cells against drug action. However, our study dem-
onstrates that the stop-Xow procedure was safely performed
on these nine patients with various advanced abdominal
malignancies. The toxicity was evaluated as acceptable
until a dose level of 1,125 mg/m2 and the regional exposure
to an anticancer agent could be enhanced dramatically
using an optimised perfusion technique. In the future, it
should be possible to treat patients with this approach using
bioreductive drugs such as mitomycin C, melphalan, or
tirapazamine—a more recently developed agent currently
under clinical development [32]. Another promising strat-
egy may consist in delivering hypoxia-selective gene ther-
apy or targeted therapy directed against the hypoxia
inducible factor 1 (HIF-1), expressed at high levels in most
cancer cells [33]. Before assessing whether these new drugs
improve the response to chemotherapy, another phase I trial
with escalating doses would be warranted in order to study
their toxicity.
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